AVCN
AVICANNA INC
stock TSE

*Acquisition of Medical Cannabis by Shoppers assets leading to the launch of MyMedi.ca.*
*Record revenue of $6.27M, representing an increase of 90% over Q2, and 713% year-over-year.*
*Improvements in performance including 46% consolidated gross margins and adjusted EBITDA of ($400k)* 
**TORONTO, NOVEMBER 14, 2023 (GLOBE NEWSWIRE) –** Avicanna Inc. (“**Avicanna**” or the “**Company**) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the commercialization of proprietary cannabinoid-based products and medical cannabis care platform is pleased to announce the results of Q3 2023.
**“**We had the boldness to take on the challenge of acquiring the Medical Cannabis by Shoppers business and executed on integrating it into the newly developed MyMedi.ca to with a goal of being able to offer a comprehensive medical cannabis care platform and improve access for Canadian patients. We have remained dedicated and focused on evidence based medical application of cannabinoids and during this quarter we have solidified our business model and our capability to scale the business” stated Aras Azadian, CEO of Avicanna Inc.
**Financial highlights:**
​
* Record revenue of $6.27M, representing an increase of 90% over the previous quarter and 713% over the same period last year.
* A 9-month revenue of $10.7M, representing a major milestone in the Company’s history a 269% growth from the same period last year.
* Scalability of the business model was demonstrated with a comparable increase of 23% in SG&A for the nine-month period.
* Best three-month financial performance in the Company’s history with an adjusted EBITDA loss of $473,000 or loss of $0.01 per share during the third quarter.
* Improved consolidated gross margins of 47% through developments in operational efficiencies.
Phil Cardella, CFO added **“**We are extremely proud to have turned the corner and accomplished the major milestone of an eight-digit revenue figure for the first time in the Company’s history. The substantial increase in high margin revenue, coupled with improvements in our working capital, and balance sheet are a testament to the Company’s innovation and commercial platforms delivering a great portfolio of products and services. We look forward to our own going efforts towards sustainable growth, profitability, and self-reliance.”
**Launch of** **MyMedi.ca medical cannabis care platform:** Launch of MyMedi.ca saw over 96% of active patients from Medical Cannabis by Shoppers business transitioned to the Company’s new medical cannabis care platform and has since increased its new medical patient base by approximately 10%. The Company developed infrastructure to offer insurance reimbursement services for patients through several private insurance providers and public institutions including eight provincial worker safety boards which combined account for over 60% of the platform’s revenue.
The integration of MyMedi.ca’s platform and patient support programs, improved access and enhanced education have resulted an 40% increase of the Company’s product sales on the platform when compared to the previous quarter.
**Canadian commercial advancements:** The launch of new proprietary formulations totalling 27 commercially active SKUs in Canada across 131 listings in medical and adult use channel. Access to the Company’s proprietary medical products improved for patients with availability on new medical platforms such as Canna Farms and Spectrum Therapeutics.
**About Avicanna Inc.**
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments.
Pr-> [https://www.avicanna.com/avicanna-reports-q3-2023-results/](https://www.avicanna.com/avicanna-reports-q3-2023-results/)

*Acquisition of Medical Cannabis by Shoppers assets leading to the launch of MyMedi.ca.*
*Record revenue of $6.27M, representing an increase of 90% over Q2, and 713% year-over-year.*
*Improvements in performance including 46% consolidated gross margins and adjusted EBITDA of ($400k)* 
**TORONTO, NOVEMBER 14, 2023 (GLOBE NEWSWIRE) –** Avicanna Inc. (“**Avicanna**” or the “**Company**) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the commercialization of proprietary cannabinoid-based products and medical cannabis care platform is pleased to announce the results of Q3 2023.
**“**We had the boldness to take on the challenge of acquiring the Medical Cannabis by Shoppers business and executed on integrating it into the newly developed MyMedi.ca to with a goal of being able to offer a comprehensive medical cannabis care platform and improve access for Canadian patients. We have remained dedicated and focused on evidence based medical application of cannabinoids and during this quarter we have solidified our business model and our capability to scale the business” stated Aras Azadian, CEO of Avicanna Inc.
**Financial highlights:**
​
* Record revenue of $6.27M, representing an increase of 90% over the previous quarter and 713% over the same period last year.
* A 9-month revenue of $10.7M, representing a major milestone in the Company’s history a 269% growth from the same period last year.
* Scalability of the business model was demonstrated with a comparable increase of 23% in SG&A for the nine-month period.
* Best three-month financial performance in the Company’s history with an adjusted EBITDA loss of $473,000 or loss of $0.01 per share during the third quarter.
* Improved consolidated gross margins of 47% through developments in operational efficiencies.
Phil Cardella, CFO added **“**We are extremely proud to have turned the corner and accomplished the major milestone of an eight-digit revenue figure for the first time in the Company’s history. The substantial increase in high margin revenue, coupled with improvements in our working capital, and balance sheet are a testament to the Company’s innovation and commercial platforms delivering a great portfolio of products and services. We look forward to our own going efforts towards sustainable growth, profitability, and self-reliance.”
**Launch of** **MyMedi.ca medical cannabis care platform:** Launch of MyMedi.ca saw over 96% of active patients from Medical Cannabis by Shoppers business transitioned to the Company’s new medical cannabis care platform and has since increased its new medical patient base by approximately 10%. The Company developed infrastructure to offer insurance reimbursement services for patients through several private insurance providers and public institutions including eight provincial worker safety boards which combined account for over 60% of the platform’s revenue.
The integration of MyMedi.ca’s platform and patient support programs, improved access and enhanced education have resulted an 40% increase of the Company’s product sales on the platform when compared to the previous quarter.
**Canadian commercial advancements:** The launch of new proprietary formulations totalling 27 commercially active SKUs in Canada across 131 listings in medical and adult use channel. Access to the Company’s proprietary medical products improved for patients with availability on new medical platforms such as Canna Farms and Spectrum Therapeutics.
**About Avicanna Inc.**
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments.
Pr-> [https://www.avicanna.com/avicanna-reports-q3-2023-results/](https://www.avicanna.com/avicanna-reports-q3-2023-results/)